Lentigen

Lentigen Corporation, a biotechnology company, engages in the development and commercialization of gene delivery technologies for human disease. It provides lentiviral vector technology for a range of therapeutic, vaccine, and research applications in biotechnology and medicine. The company offers LG690, a cell therapy for treatment of graft vs hot diseases; LG768, a cancer vaccine for the treatment of leukemia; stem cell therapy to prevent and treat medical disorders; LG631, a treatment that makes chemotheraphy for brain cancer less toxic; LG889, a steam cell therapy for hemophilia; LG611, an exact strain matched influenza vaccine for pandemic flu; LG811, an exact strain matched influenza vaccine for seasonal flu; LG747, a biosimilar erytho poieitin; and LG888, a novel factor VIII protein therapy for Hemophilia A. Lentigen Corporation was founded in 2004 and is headquartered in Gaithersburg, Maryland.

Lentigen headquartered in United States, North America, operates in the Biotechnology, Genetics sector. The company focuses on Biotechnology and has secured $19.2M in funding across 16 round(s). With a team of 11-50 employees, Lentigen is actively contributing to advancements in Biotechnology. Their latest funding round, Grant - Lentigen, raised $1.2M. Discover more about their projects, partnerships, and impact on our platform.